158 related articles for article (PubMed ID: 28982830)
21. Describing perspectives of health care professionals on active surveillance for the management of prostate cancer.
Pang K; Fitch M; Ouellet V; Chevalier S; Drachenberg DE; Finelli A; Lattouf JB; So A; Sutcliffe S; Tanguay S; Saad F; Mes-Masson AM
BMC Health Serv Res; 2018 Jun; 18(1):430. PubMed ID: 29884180
[TBL] [Abstract][Full Text] [Related]
22. Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW - Hormonal therapy, Active Surveillance, Radiation, Operation, Watchful Waiting).
Ansmann L; Winter N; Ernstmann N; Heidenreich A; Weissbach L; Herden J
BJU Int; 2018 Sep; 122(3):401-410. PubMed ID: 29603553
[TBL] [Abstract][Full Text] [Related]
23. Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer.
Egger SJ; Calopedos RJ; O'Connell DL; Chambers SK; Woo HH; Smith DP
Eur Urol; 2018 Jun; 73(6):859-867. PubMed ID: 28851582
[TBL] [Abstract][Full Text] [Related]
24. A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy.
Banerji JS; Hurwitz LM; Cullen J; Wolff EM; Levie KE; Rosner IL; Brand TC; LʼEsperance JO; Sterbis JR; Porter CR
Urol Oncol; 2017 May; 35(5):234-242. PubMed ID: 28110975
[TBL] [Abstract][Full Text] [Related]
25. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
[TBL] [Abstract][Full Text] [Related]
26. Development of patient decision support tools for motor neuron disease using stakeholder consultation: a study protocol.
Hogden A; Greenfield D; Caga J; Cai X
BMJ Open; 2016 Apr; 6(4):e010532. PubMed ID: 27053272
[TBL] [Abstract][Full Text] [Related]
27. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.
Van Hemelrijck M; Ji X; Helleman J; Roobol MJ; van der Linden W; Nieboer D; Bangma CH; Frydenberg M; Rannikko A; Lee LS; Gnanapragasam VJ; Kattan MW; ;
Eur Urol; 2019 Mar; 75(3):523-531. PubMed ID: 30385049
[TBL] [Abstract][Full Text] [Related]
28. Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center.
Thomsen FB; Mikkelsen MK; Hansen RB; Krug AH; Glenthøj A; Stattin P; Brasso K
Acta Oncol; 2016 Dec; 55(12):1456-1460. PubMed ID: 27333339
[TBL] [Abstract][Full Text] [Related]
29. Providing person-centred care for people with multiple chronic conditions: protocol for a qualitative study incorporating client and staff perspectives.
Peart A; Lewis V; Barton C; Brown T; White J; Gascard D; Russell G
BMJ Open; 2019 Oct; 9(10):e030581. PubMed ID: 31594885
[TBL] [Abstract][Full Text] [Related]
30. PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer: rationale and design.
Ahlberg MS; Adami HO; Beckmann K; Bertilsson H; Bratt O; Cahill D; Egevad L; Garmo H; Holmberg L; Johansson E; Rannikko A; Van Hemelrijck M; Jäderling F; Wassberg C; Åberg UWN; Bill-Axelson A
BMJ Open; 2019 Aug; 9(8):e027860. PubMed ID: 31444180
[TBL] [Abstract][Full Text] [Related]
31. Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists.
Kim SP; Shah ND; Meropol NJ; Tilburt JC; Nguyen PL; Yu JB; Abouassaly R; Kim A; Gross CP
Eur Urol Oncol; 2019 Mar; 2(2):189-195. PubMed ID: 31017095
[TBL] [Abstract][Full Text] [Related]
32. Patient Factors That Influence How Physicians Discuss Active Surveillance With Low-Risk Prostate Cancer Patients: A Qualitative Study.
Brooks JV; Ellis SD; Morrow E; Kimminau KS; Thrasher JB
Am J Mens Health; 2018 Sep; 12(5):1719-1727. PubMed ID: 29973123
[TBL] [Abstract][Full Text] [Related]
33. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
34. Management of erectile dysfunction after prostate cancer treatment: cross-sectional surveys of the perceptions and experiences of patients and healthcare professionals in the UK.
Dyer A; Kirby M; White ID; Cooper AM
BMJ Open; 2019 Oct; 9(10):e030856. PubMed ID: 31585974
[TBL] [Abstract][Full Text] [Related]
35. Delivering safe and effective test-result communication, management and follow-up: a mixed-methods study protocol.
Dahm MR; Georgiou A; Westbrook JI; Greenfield D; Horvath AR; Wakefield D; Li L; Hillman K; Bolton P; Brown A; Jones G; Herkes R; Lindeman R; Legg M; Makeham M; Moses D; Badmus D; Campbell C; Hardie RA; Li J; McCaughey E; Sezgin G; Thomas J; Wabe N
BMJ Open; 2018 Feb; 8(2):e020235. PubMed ID: 29449297
[TBL] [Abstract][Full Text] [Related]
36. Codesigning a patient support portal with health professionals and men with prostate cancer: An action research study.
Shemesh B; Opie J; Tsiamis E; Ayton D; Satasivam P; Wilton P; Gough K; Lewis K; O'Brien C; Shub M; Pomery A; Mac Manus C; Millar J; Evans S
Health Expect; 2022 Aug; 25(4):1319-1331. PubMed ID: 35411697
[TBL] [Abstract][Full Text] [Related]
37. What is multidisciplinary cancer care like in practice? a protocol for a mixed-method study to characterise ambulatory oncology services in the Australian public sector.
Nic Giolla Easpaig B; Arnolda G; Tran Y; Bierbaum M; Lamprell K; Delaney GP; Liauw W; Chittajallu R; Winata T; Ward RL; Currow DC; Olver I; Karnon J; Westbrook J; Braithwaite J
BMJ Open; 2019 Oct; 9(10):e031179. PubMed ID: 31601594
[TBL] [Abstract][Full Text] [Related]
38. Determining the role and responsibilities of the Australian epilepsy nurse in the management of epilepsy: a study protocol.
Rapport F; Hutchinson K; Herkes GK; Bleasel A; Nikpour A; Ryder T; Wong C; Bartley M; Ireland C; Coleman H; Todd L; Groot W; Kerr M; Vagholkar S; Shears G; Braithwaite J
BMJ Open; 2021 Jan; 11(1):e043553. PubMed ID: 33495260
[TBL] [Abstract][Full Text] [Related]
39. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
40. Healthcare costs among men with favorable risk prostate cancer managed with observation strategies versus immediate treatment in an integrated healthcare system.
Kariburyo F; Wang Y; Cheng IE; Wang L; Morgenstern D; Asner I; Xie L; Meadows E; Danella J
J Med Econ; 2017 Aug; 20(8):825-831. PubMed ID: 28534659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
